Evommune, Inc. EVMN 深 沪
等待开盘 02-04 09:30:00 美东时间
18.48
-0.750
-3.90%
华盛通- 最 高19.80
- 今 开19.29
- 成交量 15.32万股
- 最 低 17.745
- 昨 收 19.23
- 总市值 5.56亿
- 52周最高 24.03
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 13.885
- 委 比 0.00%
- 总股本 3007.76万
- 历史最高 24.03
- 量 比 0.34
- 振 幅 10.69%
- 历史最低 13.885
- 每 手 1
- 风险率 1.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
Oppenheimer Initiates Coverage On Evommune with Outperform Rating, Announces Price Target of $42
Oppenheimer analyst Andreas Argyrides initiates coverage on Evommune (NYSE:EVMN) with a Outperform rating and announces Price Target of $42.
01-22 22:19
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
HC Wainwright & Co. Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $35
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Evommune (NYSE:EVMN) with a Buy rating and announces Price Target of $35.
01-06 19:56
Analysts’ Top Healthcare Picks: Ceribell, Inc. (CBLL), Evommune, Inc. (EVMN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
01-06 01:50
美股牛股 | 太空概念股普涨，LUNR涨近38%；爱美医疗涨超30%，获拜玛林制药48亿美元收购
NovaBay Pharmaceuticals涨79.7%；Lunar Corporation涨37.7%；D-MARKET Electronic Services & Trading涨37.1%
2025-12-20 10:49
Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones index gaining more than 250 points ...
2025-12-20 01:07
Evommune, Inc. GAAP EPS of -$8.07, revenue of $10M
Evommune, Inc. press release (EVMN): Q3 GAAP EPS of -$8.07. Revenue of $10M. As of September 30, 2025, the Company had cash, cash equivalents and investments of $76.0 million, compared to $72.0 millio...
2025-12-12 05:15
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
2025-12-02 09:50
